LYRA.US Lyra Therapeutics Inc

Healthcare Biotechnology USA Stocks
0.1900 USD
Close of Nov 15, 2026
0.0004 4.59
Market cap
USD 337K
P/E
-
P/B
7.10x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is LYRA.US undervalued?

Graham number

The Graham number of Lyra Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Lyra Therapeutics Inc fundamental analysis

No fundamental analysis for Lyra Therapeutics Inc yet.

Lyra Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Lyra Therapeutics Inc

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the tre…

Full company profile